Automated analysis of gray matter damage in aged mice reveals impaired remyelination in the cuprizone model
Brain Pathology · 2024-03 · 34 (2)
DOI: 10.1111/bpa.13218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 05.11.2023. Verfasst von Stefan Gingele und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Demyelinating Diseases, Remyelination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Multiple sclerosis is a chronic autoimmune disease of the central nervous system characterized by myelin loss, axonal damage, and glial scar formation. Still, the underlying processes remain unclear, as numerous pathways and factors have been found to be involved in the development and progression of the disease. Therefore, it is of great importance to find suitable animal models as well as reliable methods for their precise and reproducible analysis. Here, we describe the impact of demyelination on clinically relevant gray matter regions of the hippocampus and cerebral cortex, using the previously established cuprizone model for aged mice. We could show that bioinformatic image analysis methods are not only suitable for quantification of cell populations, but also for the assessment of de‐ and remyelination processes, as numerous objective parameters can be considered for reproducible measurements. After cuprizone‐induced demyelination, subsequent remyelination proceeded slowly and remained incomplete in all gray matter areas studied. There were regional differences in the number of mature oligodendrocytes during remyelination suggesting region‐specific differences in the factors accounting for remyelination failure, as, even in the presence of oligodendrocytes, remyelination in the cortex was found to be impaired. Upon cuprizone administration, synaptic density and dendritic volume in the gray matter of aged mice decreased. The intensity of synaptophysin staining gradually restored during the subsequent remyelination phase, however the expression of MAP2 did not fully recover. Microgliosis persisted in the gray matter of aged animals throughout the remyelination period, whereas extensive astrogliosis was of short duration as compared to white matter structures. In conclusion, we demonstrate that the application of the cuprizone model in aged mice mimics the impaired regeneration ability seen in human pathogenesis more accurately than commonly used protocols with young mice and therefore provides an urgently needed animal model for the investigation of remyelination failure and remyelination‐enhancing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hannover Medical School, Hannover, Germany.
- Department of Translational Medicine Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
ORCID-Profile: Viktoria Gudi
Zitieren
APA
Gingele, S., Möllenkamp, T. M., Henkel, F., Schröder, L. J., Hümmert, M. W., Skripuletz, T., Stangel, M., & Gudi, V. (2024). Automated analysis of gray matter damage in aged mice reveals impaired remyelination in the cuprizone model. Brain Pathology, 34(2). https://doi.org/10.1111/bpa.13218
Vancouver
Gingele S, Möllenkamp TM, Henkel F, Schröder LJ, Hümmert MW, Skripuletz T, et al. Automated analysis of gray matter damage in aged mice reveals impaired remyelination in the cuprizone model. Brain Pathology. 2024;34(2). doi:10.1111/bpa.13218
BibTeX
@article{Gingele2024,
author = {Gingele, Stefan and Möllenkamp, Thiemo M and Henkel, Florian and Schröder, Lara-Jasmin and Hümmert, Martin W and Skripuletz, Thomas and Stangel, Martin and Gudi, Viktoria},
title = {Automated analysis of gray matter damage in aged mice reveals impaired remyelination in the cuprizone model},
journal = {Brain Pathology},
year = {2024},
volume = {34},
number = {2},
doi = {10.1111/bpa.13218}
}
EUVIMED